Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4
26 Février 2024 - 2:00PM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical
company focused on transforming medicines to transform lives,
announced today that it will host a conference call and live
webcast at 7:30 a.m. ET on Monday, March 4, 2024, to provide a
corporate update and discuss the Company's financial results for
the fourth quarter and full year ended December 31, 2023.
Avadel plans to issue its Annual Report on Form 10-K for the
year ended December 31, 2023, on Thursday, February 29.
A live audio webcast of the call can be accessed by visiting the
investor relations section of the Company’s website,
www.avadel.com. A replay of the webcast will be archived on
Avadel’s website for 90 days following the event. Participants may
register for the conference call here and are advised to do so at
least 10 minutes prior to joining the call.
About Avadel Pharmaceuticals plcAvadel
Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company
focused on transforming medicines to transform lives. Our approach
includes applying innovative solutions to the development of
medications that address the challenges patients face with current
treatment options. Avadel’s commercial product, LUMRYZ™, was
approved by the U.S. Food & Drug Administration (FDA) as the
first and only once-at-bedtime oxybate for the treatment of
cataplexy or excessive daytime sleepiness (EDS) in adults with
narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:Courtney MogerleyStern
Investor Relations, Inc.Courtney.Mogerley@sternir.com (212)
698-8687
Media Contact:Lesley StanleyReal
Chemistrylestanley@realchemistry.com (609) 273-3162
Avadel Pharmaceuticals (NASDAQ:AVDL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024